Impact of sitagliptin on endometrial mesenchymal stem-like progenitor cells : a randomised, double-blind placebo-controlled feasibility trial

[thumbnail of WRAP-impact-sitagliptin-endometrial-mesenchymal-stem-like-progenitor-cells-Quenby-2020.pdf]
Preview
PDF
WRAP-impact-sitagliptin-endometrial-mesenchymal-stem-like-progenitor-cells-Quenby-2020.pdf - Published Version - Requires a PDF viewer.
Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0.

Download (725kB) | Preview

Request Changes to record.

Abstract

Background:
Recurrent pregnancy loss (RPL) is associated with the loss of endometrial mesenchymal stem-like progenitor cells (eMSC). DPP4 inhibitors may increase homing and engraftment of bone marrow-derived cells to sites of tissue injury. Here, we evaluated the effect of the DPP4 inhibitor sitagliptin on eMSC in women with RPL, determined the impact on endometrial decidualization, and assessed the feasibility of a full-scale clinical trial.
Methods:
A double-blind, randomised, placebo-controlled feasibility trial on women aged 18 to 42 years with a history of 3 or more miscarriages, regular menstrual cycles, and no contraindications to sitagliptin. Thirty-eight subjects were randomised to either 100 mg sitagliptin daily for 3 consecutive cycles or identical placebo capsules. Computer generated, permuted block randomisation was used to allocate treatment packs. Colony forming unit (CFU) assays were used to quantify eMSC in midluteal endometrial biopsies. The primary outcome measure was CFU counts. Secondary outcome measures were endometrial thickness, study acceptability, and first pregnancy outcome within 12 months following the study. Tissue samples were subjected to explorative investigations.
Findings:
CFU counts following sitagliptin were higher compared to placebo only when adjusted for baseline CFU counts and age (RR: 1.52, 95% CI: 1.32–1.75, P<0.01). The change in CFU count was 1.68 in the sitagliptin group and 1.08 in the placebo group. Trial recruitment, acceptability, and drug compliance were high. There were no serious adverse events. Explorative investigations showed that sitagliptin inhibits the expression of DIO2, a marker gene of senescent decidual cells.
Interpretation:
Sitagliptin increases eMSCs and decreases decidual senescence. A large-scale clinical trial evaluating the impact of preconception sitagliptin treatment on pregnancy outcome in RPL is feasible and warranted.
Funding:
Tommy's Baby Charity.
Clinical trial registration:
EU Clinical Trials Register no. 2016-001120-54.

Item Type: Journal Article
Subjects: Q Science > QH Natural history
Q Science > QP Physiology
R Medicine > R Medicine (General)
R Medicine > RG Gynecology and obstetrics
Divisions: Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Biomedical Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences
Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School
Library of Congress Subject Headings (LCSH): Pregnancy -- Complications -- Research, Miscarriage -- Research, Endometrium, Stem cells, Decidua, Clinical trials
Journal or Publication Title: EBioMedicine
Publisher: Elsevier BV
ISSN: 2352-3964
Official Date: 9 January 2020
Dates:
Date
Event
9 January 2020
Published
10 December 2019
Accepted
Volume: 51
Article Number: 102597
DOI: 10.1016/j.ebiom.2019.102597
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Open Access (Creative Commons open licence)
Date of first compliant deposit: 10 January 2020
Date of first compliant Open Access: 20 January 2020
RIOXX Funder/Project Grant:
Project/Grant ID
RIOXX Funder Name
Funder ID
UNSPECIFIED
Tommy's Baby Charity
UNSPECIFIED
Juntendo University
URI: https://wrap.warwick.ac.uk/131794/

Export / Share Citation


Request changes or add full text files to a record

Repository staff actions (login required)

View Item View Item